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Abstract
A single correlate of effective vaccine protection against chronic HCV infection has yet to be defined. In this study, we
analyzed T-cell responses in four chimpanzees, immunized with core-E1-E2-NS3 and subsequently infected with HCV1b.
Viral clearance was observed in one animal, while the other three became chronically infected. In the animal that cleared
infection, NS3-specific CD8 T-cell responses were observed to be more potent in terms of frequency and polyfunctionality of
cytokine producing cells. Unique to this animal was the presence of killing-competent CD8 T-cells, specific for NS31258–1272,
being presented by the chimpanzee MHC class I molecule Patr-A*03:01, and a high affinity recognition of this epitope. In the
animals that became chronically infected, T-cells were able to produce cytokines against the same peptide but no cytolysis
could be detected. In conclusion, in the animal that was able to clear HCV infection not only cytokine production was
observed but also cytolytic potential against specific MHC class I/peptide-combinations.
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Introduction
Hepatitis C virus (HCV) infection is characterized by a high
propensity for development of chronic infection, which typically
manifests as asymptomatic for a long period of time. However,
over decades the virus causes subtle, but cumulatively irreversible,
hepatic damage. A vaccine that could prevent development of
persistent HCV infection would therefore be of great clinical
benefit.
The chimpanzee is the only validated animal model of HCV
infection [1,2]. The dilemma that biomedical research in non-
human primates, and chimpanzees in particular, is inevitably
associated with low animal numbers and limiting statistical
analysis, has been discussed elsewhere [3]. Nevertheless, we
believe that results from in depth immune-profiling of immunized
chimpanzees may provide new insights into immune mechanisms
operating in the early phase after infection and as such is
important for optimal vaccine development in the future.
Spontaneous HCV clearance has been associated with the
presence of broad and strong T-cell responses in both humans and
chimpanzees [4–7]. Moreover, specific memory T-cell responses
often correlate with early clearance after HCV reinfection [8–10].
These data imply that T-cell-based vaccines may facilitate HCV
clearance, protect from viral persistence and thus from HCV-
related disease progression.
For this reason, several HCV T-cell vaccine-candidates
have been evaluated. Some of these vaccine-strategies induced
strong T-cell responses however, no correlation was observed
between either the magnitude or the breadth of vaccine-induced
T-cell responses, and viral clearance. The lytic capacity of vaccine-
induced CD8 T-cells, in the context of MHC class-I presentation
was not previously evaluated in relation to viral clearance.
Previously, we reported partial control of an HCV 1b challenge
after a DNA prime-MVA-boost vaccine strategy, targeting HCV
core, E1, E2 and NS3 in chimpanzees [11]. In these animals,
neither (neutralizing) antibody responses nor ex vivo cytokine
production or proliferative responses were uniquely associated
with control of HCV infection. Therefore, the current study aimed
to identify potential mechanisms of protection via detailed
functional characterization of the T-cell responses against the
most dominantly recognized antigen, NS3 [11].
We report that the animal that cleared infection had a high
percentage of polyfunctional cytokine producing CD4 and CD8
T-cells against NS3-peptides. Moreover, a strong cytolytic T-cell
(CTL) response against epitope NS31258–1272 was identified, which
was uniquely presented in the context of the chimpanzee MHC
class I molecule Patr-A*03:01.
Materials and Methods
Ethics statement
This retrospective study was performed on cryopreserved
PBMCs, isolated from animals that were part of an HCV
vaccine-efficacy study [11]. As previously described, the preceding
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study had been performed in six purpose bred, naive mature
chimpanzees (Pan troglodytes) that were housed at the Biomedical
Primate Research Centre (BPRC), Rijswijk, The Netherlands,
according to international guidelines for non-human primate care
and use (The European Council Directive 86/609/EEC, and
Convention ETS 123, including the revised Appendix A). The
Institutional Animals Care and Use Committee (DEC-BPRC)
approved study protocols (#426) according to strict international
ethical and scientific standards and guidelines. The qualification of
the members of this committee, including their independence from
a research institute, is stated in the ‘‘Wet op de Dierproeven’’
(1996). The experiment can only be performed after a positive
recommendation from this ethical committee. Permission for
projects on non-human primates is requested in an animal ethical
committee form. This form is discussed in the ethical committee
and, if approved, a written permission is sent to the project leader
and a copy to the director of the BPRC, who holds licence to
perform animal experimentation. The project was monitored by a
qualified independent veterinarian, specifically regarding the
ethical issues of the projects.
The animals were in good physical health with normal
biochemical and hematological values. The animals were socially
housed in a BSL3-facility with spacious cages, and were provided
with commercial food pellets supplemented with appropriate
treats. Drinking water was provided ad libitum. Environmental
enrichment was provided daily and suffering of the animals was
alleviated wherever possible. In 2002, the European Council
banned the use of apes for biomedical research in Europe. Yet, this
was decided after the initiation of the original vaccine-study
described by Rollier et. al. [11]. For this reason, the European
Council approved continuation of this particular study. The
following years, all chimpanzees that were housed at the BPRC
were outplaced to public zoos or animal sanctuaries. Before 2001,
the use of chimpanzees for biomedical research was highly
restricted and regulated, it was not allowed to perform terminal
experiments on these animals [12].
Peptide-pools
For stimulation and expansion of HCV-specific cells, two
different NS3-peptide-pools were compiled: NS3vaccine was a
mixture of 15-mer peptides with 11 amino acids overlap, covering
the NS3-sequence of the vaccine constructs; NS3challenge was a
mixture of 15-mer peptides with 11 amino acids overlap covering
the NS3-variants observed in the inoculum. Identification of NS3
epitopes within NS3 was first performed via the matrix setup [13]
and confirmed in a second assay using individual peptides
(peptide-sequences are listed in Table S1).
In vitro expansion of NS3-specific T-cell lines
Cells isolated before infection were expanded and tested for
response against peptide-pool NS3vaccine, whereas cells isolated
after challenge were tested against peptide-pool NS3challenge.
PBMCs isolated at the day of challenge were stimulated in two
separate cultures with either NS3vaccine or NS3challenge.
After thawing, PBMCs were washed and resuspended in culture
medium, R20 (RPMI, Invitrogen, CA, USA) supplemented with
20% FCS (MP medicals, Solon, OH, USA), pen/strep (100 U/
ml/100 mg/ml) (Invitrogen) and L-glutamine (2 mM) (Invitrogen))
and cultured at a final density of 10 million cells per ml in a 24 well
culture plate (Greiner bio-one). The cultures were initiated in R20
containing 5 ng/ml IL-7 (Peprotech) and NS3-peptide-pool (5 mg/
ml per peptide). After overnight incubation, 1 ml R20 containing
IL-7 (10 ng/ml) and IL-2 (Proleukin Chiron, final concentration
10 IU/ml) was added per well. Cultures were checked daily for
general condition and depending on cell density, fresh R20 IL-2/
IL-7 was added or cultures were split. After 12 days, the expanded
cells were collected and resuspended in fresh R20 for further
analysis.
T-cell epitope mapping
The cytokine production profile of HCV-specific T-cell lines
was determined by intracellular cytokine staining (ICS) after
restimulation with NS3-peptides. For T-cell epitope mapping
0.26106 expanded cells were either restimulated with NS3-
peptide-pool (1 mg/ml/peptide) or without NS3-peptide, in
medium containing co-stimulatory aCD28 and aCD49d mole-
cules (2 mg each, BD-Biosciences) and 5% FCS (MP-Biomedicals).
After 2 hrs, Brefeldin A (Golgiplug 1:1000, BD-Biosciences) was
added and 16 hours later the surface markers were stained with a
panel of fluorochrome labeled antibodies, containing CD3-
PacificBlue (clone SP-34-2, (BD-Pharmingen), CD14-PE-Tex-
asRed (clone RMO52, BeckmanCoulter), CD20-PE-TexasRed
(clone B9E9, BeckmanCoulter), CD4-PE-Cy7 (clone SK3, BD-
Pharmingen) and CD8-APC-H7 (clone SK1, BD-Pharmingen).
Stained cells were fixed and permeabilized (Cytofix/Cytoperm,
BD Biosciences), followed by staining of accumulated intracellular
cytokines with IFNc-APC (clone B27, BD Pharmingen), IL-2-PE
(clone MQ1-17H12, BD Pharmingen) and TNFa-FITC (clone
MAb11, BD Pharmingen). Cell staining was analyzed on a
FACSAria (BD Bioscience) and DIVA software Version 6.1.1.
To evaluate antigen sensitivity, T-cell lines were restimulated
with increasing concentrations of individual peptide ranging from
0.05 to 10 mg/ml before intracellular cytokine production was
measured.
MHC-class-I genotyping
Animals were genotyped for their MHC-class-I repertoire as
previously described [14] (Table 1).
Non-radioactive cytotoxicity assay
NS3-peptide-specific T-cell lines were tested for their capacity to
kill peptide-loaded target cells, using a new non-radioactive
cytotoxicity assay. In this assay, a panel of matched Patr MHC-
class-I expressing transfectants, either constructed in 721.221 cells
(kindly provided by C. Walker, Center for Vaccines and
Immunity, The Ohio State University) or K562 [15] were used
as target cells. In brief, 36106 MHC-matched transfected target
cells were labeled with 1 mM CFSE (CFSElow) (Fluka) and another
36106 MHC-matched transfected target cells, expressing the same
class-I molecule were labeled with 8 mM CFSE (CFSEhigh).
Subsequently, CFSElow cells were incubated with medium alone,
whereas, CFSEhigh target cells were pulsed with HCV-peptide
(8 mg/ml) for 2 hrs at 37uC. Excess peptide was removed by
Table 1. MHC class I genotypes of the chimpanzees.
Patr class I alleles
Patr-A Patr-B
Vac1 A*03:01 A*04:04 B*02:01 B*03:01
Vac2 A*06:01 A*04:01 B*01:01 B*03:01
Vac3 A*09:01 -A B*01:01 B*02:01
Vac4 A*09:01 A*0101 B*01:01 B*16:0101
AVac3 is likely to be homozygous A*0901.
doi:10.1371/journal.pone.0095103.t001
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washing before mixing CFSEhigh and CFSElow with 16106 NS3-
specific expanded T-cells (ET ratio 10:1). The mixed target and
effector cells were cocultured for 16 hrs, after which CFSE staining
was analyzed using a FACSAria (BD Bioscience) and DIVA
software Version 6.1.1.
Specific lysis was calculated using the following formula;
%specific lysis~
100- highpeptide  lowmock
 
= lowpeptide  highmock 
 
 100
 
and lysis was considered positive when exceeding 25%.
Peptide-binding assay
A cell-based peptide-binding-competition-assay was performed
as previously described [15]. In this assay, peptides are tested for
binding to transfected cell lines expressing chimpanzee class-I
molecules, while competing with a biotin-labeled reference-
peptide. In a 96 wells plate, 100.000 MHC class-I transfected
K562 or 721.221 cells were incubated with 500nM of the
biotinylated-indicator-peptide (in case of A*03:01 ATALECVYK
was used, and in case of B*01:01 LSDMHLCSI, in which C
indicates the position of the biotin-labeled cysteine) and 0.05 to
100 nM of the peptide of interest, for instance p59 (NS31258–1272),
LGFGAYMSK or AATLGFGAY. Peptide KGGLRPRAG,
predicted to have no or a very low binding affinity to MHC class
I molecules based on the incorporation of glycines on the anchor
positions, was used as control. After overnight incubation, excess
peptide was removed by washing and indicator-peptide bound to
cells was quantified using the DELFIA-system and the Victor3
1420 multilabel counter (Perkin Elmer). The binding affinity of the
indicator peptide was verified using its unlabeled peptide as
competitor, this is referred to as standardized competitor [15].
Results
Characterization of NS3 specific CD4 and CD8 T-cell
cytokine responses
We previously reported [11] an HCV-vaccine evaluation-study
in chimpanzees, in which 4 out of 4 immunized animals became
viremic shortly after challenge with HCV 1b J4. However, at a
later stage, animal Vac1 cleared HCV infection while the three
other animals, Vac2, Vac3 and Vac4 became chronically infected.
As reported previously, IFNc release, ex vivo lymphoproliferative
responses, Th1/Th2 cytokine release patterns, and HCV-specific
antibodies were comparable amongst the four animals [11]. NS3
was the immunodominant antigen in all four animals, while the
responses against core, E1 and E2 were not only less intense, but
also largely absent in Vac1, the animal which was protected
against chronic infection. Therefore, functional analysis of the
cellular responses was focused on the immunodominant NS3
antigen [11].
After 12 days of culturing in the presence of a pool of NS3
peptides, T-cell lines were restimulated with individual peptides
and analyzed for intracellular expression of IFNc, IL-2 and TNFa
using the gating strategy shown in Figure S1. Cells within the
lymphocyte gate that were CD3 positive, and CD14 and CD20
negative were selected and subsequently IL-2, IFNc and TNFa
single, dual or triple cytokine expression was analyzed in the CD4
and CD8 T-cell subsets within the T-cell lines. Cytokine
expression profiles varied per peptide as illustrated in Figure 1.
For instance, only moderate cytokine induction was observed after
peptide specific restimulation of expanded CD4 cells in Vac1. In
contract, strong dual IFNc and IL-2 expression was seen in
expanded CD8 T-cells restimulated with peptide 59 (NS31258–1272),
while medium alone or peptide 64 (IRTGVRTITTGGPIT) did not
induce cytokine production. In comparison, in Vac2 p59 only gave
a marginal cytokine induction in expanded CD8 T-cells, while p64
induced moderate dual IFNc/IL-2 and IFNc/TNFa cytokine
production (Figure 1). Instead, expanded CD4 T-cells in Vac2,
showed stronger response towards p59.
In this manner the responses against each individual NS3
peptide was investigated and the results are summarized in
Figure 2 in the form of heat maps; showing the percentages of
IFNc producing CD4 (Figure 2(A)) and IFNc/IL-2 dual cytokine
producing CD8 (Figure 2(B)) T-cells in all four animals at all time
points tested. In general, analysis of peptide responses by dual
cytokine expression gives a clear-cut distinction between positive
and negative responses, because of low background responses.
However, for CD4 T-cells the number of dual cytokine expressing
cells was often rather low, making it necessary to consider the total
number of IFNc cytokine producing cells. The peptide recognition
profiles shown in Figures 2(A and B) indicate that some regions
within the NS3 peptide sequence, indicated by red boxes, are
broadly recognized amongst the animals. Other peptide specific
responses were more restricted and only gave positive responses at
some time points in one to two animals. No unique peptide
response-pattern could be discerned for Vac1 that could explain
vaccine induced viral clearance as compared to Vac2, 3, and 4.
Moreover, no relation was observed between the number of
peptides recognized and the course of infection (Table 2).
Next, the sum of the % of cytokine producing cells induced by
all 156 individual peptides was calculated for expanded CD4 and
CD8 lines. This total frequency of peptide-specific IFNc-produc-
ing expanded CD4 T-cells was comparable between Vac1 and
Vac2, but somewhat lower in Vac3 and Vac4 (Figure 2(C)). After
the last immunization (week -4), total peptide specific CD8 T-cell
responses were higher in Vac1 as compared to the other animals
(Figure 2(D)). Triple cytokine production, i.e. simultaneous
expression of IFNc, IL-2 and TNFa by expanded CD8 cells,
was also higher in Vac1 and for instance observed in 12.3% of the
p59-specific expanded CD8 T-cells 4 weeks prior to HCV
infection, whereas this was less than 7% in Vac2, Vac3 and
Vac4 (Figure. 2(E)).
In conclusion, we observed increased number of NS3 specific
cytokine producing expanded CD8 T-cells after the last immuni-
zation, and especially more triple IFNc, IL-2 and TNFa cytokine
producing cells in the animal that cleared the virus, relative to
those animals that became chronically infected.
Cytolytic capacity of NS3 p59 specific CD8 T-cells in Vac1
Next, NS3-peptide-specific cells were evaluated for their
capacity to kill peptide-loaded target cells. Similar to standard
51chromium release assays, T-cells were expanded prior to analysis
[6,16]. The expanded T-cells were tested for their lytic capacity for
all individual peptides that were found to induce IL-2/IFNc dual
expression in expanded CD8 cells (Figure 2(B)) and was tested
against a panel of MHC matched target cells [15] (Table 1).
Figure 3(A) illustrates specific killing of p59-pulsed CFSEhigh
relative to unpulsed CFSElow Patr-A*03:01 target cells, using
expanded T-cells from Vac1, isolated 10 weeks after HCV
challenge. As a control, no difference in ratio of the area under the
curve was observed if both the CFSEhigh and CFSE low Patr-
A*03:01 targets were unpulsed (Figure 3(C)), precluding non-
specific toxicity due to labeling with higher CFSE concentration.
Killing of target cells was only observed for particular peptide-
HCV Vaccine Chimpanzees
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MHC class I combinations. As shown in Figures 3(B and D),
neither unpulsed nor p59-pulsed Patr-B*02:01 targets were lysed
by expanded cells from Vac1.
Amongst all peptides tested, i.e. 24, 22 and 35 in Vac1, Vac2
and Vac3 respectively, highly efficient killing was only observed
against p59 in Vac1 and only when this peptide was presented by
Patr-A*03:01 (Figure 3(E to G)). Only the peptides partly
overlapping with p59 gave some lysis, while none of the other
MHC class-I-peptide-combinations exceeded 25% of specific
killing. Due to the limited number of cells after expansion, Vac4
could not be tested.
Collectively, the data show that although stimulation with p59
can induce some level of cytokine production in all vaccinees, a
p59-mediated cytolytic capacity was only observed in Vac1.
NS3p59(aa1258–1272) binds with high affinity to Patr-
A*03:01
Peptide binding to MHC-class I is determined by the anchor-
residues fitting into the B- and the F-pocket of the relevant allotype
for most MHC class-I-molecules. Usually MHC class I molecules
bind nonamer peptides, in which the p2-position of the peptide
anchors into the B-pocket and the p9-position of the peptide
anchors into the F-pocket. Peptide 59, which was observed to
initiate cytolysis when presented in the context of Patr-A*03:01,
was scanned using the NetMHCpan version 2.8 prediction
algorithm [17] against the MHC class I molecules present in the
studied cohort (Table 1). It is known that peptides that bind, or are
predicted to bind to MHC class I molecules with an affinity
,500 nm are potential T-cell epitopes [18–20]. In p59 four
potential nonamer peptides are present, AATLGFGAY, ATLGF-
GAYM, TLGFGAYMS, and LGFGAYMSK. The only combi-
nation that was predicted to bind with an affinity ,500 nm was
LGFGAYMSK in the context of Patr-A*03:01. A cell-based
peptide binding competition assay was performed to test the
binding-affinity of p59, and the nonamer peptides AATLGFGAY
and LGFGAYMSK to Patr-A*03:01 and as control to Patr-
B*01:01. The peptide binding motif of Patr-A*03:01 is defined as
X(STA)XXXXXX(RK) and for Patr-B*01:01 as
(X(ST)XXXXXX(IL) [15,21]. Figure 4 shows that all three NS3
peptides have a high binding affinity to Patr-A*03:01, with IC50
values between 0.03 to 0.2 mM, which is higher compared to the
control peptide (IC50 = 8.2 mM) and the standardized competitor
peptide of Patr-A*03:01 with IC50 = 1.5 mM [15]. Peptide
LGFGAYMSK was found to have the highest binding affinity to
Patr-A*03:01. In contrast, only low binding affinity was observed
for p59 in the context of Patr-B*01:01 as compared to its
standardized competitor (IC50 = 1.0 mM), whereas for the two
nonamer peptides, no amenable regression curves could be drawn
suggesting low or no binding affinity (not shown).
T-cells of Vac1 respond at lower peptide concentration
Antigen specific responses not only depend on the presentation
of peptides by MHC class I molecules but also on the binding of
the peptide/MHC complex to the T-cell-receptor (TCR).
Therefore, we tested whether the response-threshold of CD4
and CD8 T-cell lines from Vac1 differed from Vac2 and Vac3. To
this end, NS3-specific expanded T-cells, isolated 4 weeks prior to
HCV infection, were expanded from PBMCs, restimulated with
different concentrations of NS31258–1272 ranging from 0.05 to
10 mg/ml, and stained for intracellular IL-2 and IFNc. Expanded
CD8 T-cells from Vac1 were found to respond at a peptide
concentration as low as 0.05 mg/ml whereas, at least, 20 times
more peptide was required for CD8 T-cells from Vac2 and Vac3
(Figure 5). For IFNc production by expanded CD4 T-cells the
difference is even more striking. Here, we could hardly detect p59-
specific IFNc producing CD4 T-cells in Vac2 and Vac3 while
these cells are abundantly present in Vac1.
Discussion
The chimpanzee is the closest living relative of man and the
only validated animal model for HCV infection. The evolutionary
proximity of both species is reflected by close genetic and
immunological similarity. For these reasons the chimpanzee
provides an exquisite animal model, in which immune responses
against HCV vaccines and the effect on deliberate infection can be
Figure 1. Evaluation of peptide-specific IL-2, IFNc and TNFa expression in CD4 and CD8 T-cells. A representative example of the analysis
performed in Vac1 (left panel) and Vac2 (right panel), two weeks after the final vaccine boost, is shown. PBMC were first expanded for a 12 day period
using a pool of all NS3 peptides, restimulated with individual peptides (medium alone, p59 or p64) and analyzed for induction of IFNc, IL-2 and TNFa
cytokine expression by expanded CD4 and expanded CD8 cells, using the gating strategy described in Figure S1. The numbers in the quadrants,
represent the percentage of positive cells calculated from the parent-population.
doi:10.1371/journal.pone.0095103.g001
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investigated in an experimental setting [2]. Here, we report of an
in depth profiling of CD4 and CD8 T-cell responses in four
chimpanzees, which were immunized with an experimental
vaccine for HCV and subsequently challenged with HCV 1b J4
[11].
While all four animals became infected, only the Patr-A*03:01
positive animal was able to clear HCV infection. Detailed
mapping of CD4 and CD8 T-cell cytokine responses, and the
analysis of their cytolytic potential, revealed that expanded T-cells
of the vaccinee which effectively cleared HCV infection displayed:
a) a higher frequency of peptide-specific IL-2/IFNc dual cytokine
Figure 2. Heat map of NS3-peptide-specific T-cell responses in four immunized chimpanzees at different study time points. (A)
Percentage of expanded CD4 T-cells producing IFNc upon restimulation with individual peptides, subdivided into three categories; i.e. low response
(light green; 0.001%–0.1% specific IFNc production), intermediate (green; 0.1–1% specific response), high (dark green;.1% specific response). (B)
Percentage of expanded CD8 T-cells showing IL-2/IFNc double cytokine production upon restimulation with individual peptide, subdivided into three
categories; i.e. low response (light blue; 0.01%–0.1% specific IFNcproduction), intermediate (blue; 0.1–1% specific response), high (dark blue; . 1%
specific response). White areas indicate where no responses were detected. The red boxes highlight areas within NS3 that are broadly recognized. Per
animal 6 time points of analysis are shown lined up beneath each other; -12) Two weeks following the 1st MVA boost, cells stimulated with NS3vaccine,
-4) Four weeks following 2nd MVA boost, cells stimulated with NS3vaccine, 0) Day of HCV infection, stimulation with NS3vaccine, 0) Day of HCV infection,
stimulation with NS3challenge, and 4 and 36 weeks after challenge, stimulation with NS3challenge. The individual peptides tested are indicated at the top
of the map by the numbers 1 to 156. The red boxes represent broadly recognized regions within NS3. Total frequency (all peptide responses
combined) of (C) IFNc production by expanded CD4 T-cells and (D) IFNc/IL2 dual cytokine production by expanded CD8 T-cells per animal. (E)
Frequency of p59 specific triple positive IL2/TNFa/IFNc producing CD8 T-cells. The numbers on the X-axis represent the study week, relative to time
of challenge. * Despite several attempts, frozen cells from Vac1 from 4 weeks following HCV infection did not respond to either NS3vaccine or
NS3challenge peptide stimulation and no expansion could be achieved. @ Due to a high IFNc background, peptide specific CD8 responses could not be
detected
doi:10.1371/journal.pone.0095103.g002
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producing CD8 T-cells; b) peptide-specific TNFa production in
CD8 T-cells; c) cytolytic capacity against peptide-loaded target
cells; d) cytokine induction at a low antigen concentration for the
cytolysis-inducing peptide. Remarkably, the cytolysis-inducing
peptide p59 was found to bind strongly to Patr-A*03:01, which
was only present in Vac1. Using the NetMHCpan algorithm, it
was predicted that peptide LGFGAYMSK, one of the nonamer
peptides present in the 15-mer p59, would show the strongest
binding to Patr-A*03:01. Peptide LGFGAYMSK was also
predicted to bind to the MHC class I molecules Patr-A*01:01,
A*04:01, A*04:04, and A*09:01, present in all of the studied
animals, but only with intermediate affinity between 0.9 and
5 mM. These data are in agreement with the differences in
cytokine responses and cytolyses reported in expanded T-cells here
and could indicate a particular affinity threshold is necessary for a
peptide to induce adequate immune responses for combating
HCV. The strong binding of the 15-mer p59 to Patr-A*03:01 is
somewhat unexpected, as generally nonamer peptides bind to
MHC class I molecules. Nonetheless, in humans it has been shown
that particular MHC class I molecules are capable of binding
longer peptides with bulged structures [22,23].
Stimulation assays would give information about the biological
relevance of the binding experiments. However, the limited
number of cells stored from these animals, preclude performing
such assays.
Unlike ex vivo detection of CTL in humans, detection of these
cells in chimpanzees can often only be achieved after amplification
of antigen specific responses [6,16]. Obviously, in vitro expansion of
T-cells from frozen PBMC has its limitations. Antigen presenting
cells may be affected by the freezing/thawing process resulting in –
partly hampered- antigen presentation. Furthermore, the addition
of cytokines and peptides may skew the immune system differently
as compared to the in vivo situation.
Table 2. Number of NS3-peptides that induce IFNc
production by CD4 T-cells or IL-2/IFNc dual cytokine
production by CD8 T-cells.
TOTAL PRE POST
CD4 Vac1 34 34 11
Vac2 55 42 36
Vac3 58 51 22
Vac4 38 19 25
CD8 Vac1 22 20 8
Vac2 22 20 6
Vac3 35 22 27
Vac4 44 27 25
PRE, pre challenge. POST, post challenge.
doi:10.1371/journal.pone.0095103.t002
Figure 3. Cytolytic killing of CFSE-loaded target cells. (A) Specific lysis of NS31258–1272-pulsed Patr-A*03:01 target cells (red peak) in comparison
with unpulsed Patr-A*03:01 target cells (yellow peak) by NS3-peptide-pool expanded PBMC from Vac1 isolated 10 weeks after HCV 1bJ4 challenge
(blue peak). (B) No specific lysis of NS31258–1272-pulsed Patr-B*02:01 target cells. (C) and (D) Control experiments showing no killing of unpulsed Patr-
A*03:01 or Patr-B*02:01 target cells. (E,F,G) Percentage of lysis for all MHC class-I-peptide-combinations tested in Vac1, Vac2, Vac3 respectively.
doi:10.1371/journal.pone.0095103.g003
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To determine the degranulating capacity of T-cells, CD107a
stainings were performed on T-cell lines. However, the results of
these assays were unclear and no conclusion could be drawn from
it, basically because of the lack of a proper negative control.
Unlike in the intracellular cytokine staining assays, where the
difference between cells restimulated with peptide or medium
alone was very clear, no clear difference could be observed when
CD107a was used. Probably the expansion-protocol used here
does agree with antigen specific CD107a staining. Unfortunately,
the number of stored cells from these animals is limited and assays
like this require too many cells to repeat the assays.
And although we cannot exclude that upon further amplifica-
tion of antigen specific responses, CTL responses might also be
detectable in the other animals, our data suggest that they are of
lower magnitude.
To study the possibility of viral escape from immune pressure as
a cause of development of chronicity in Vac2, Vac3 and Vac4,
analysis of viral sequences was performed and compared with the
inoculum sequence (data not shown). Only a limited number of
amino acid substitutions were detected in the areas that overlap
with cytokine-inducing peptides. There was however no evidence
for mutational escape in the immunodominant p59 in any of the
animals.
This study highlights a potential role for CD8 mediated cytolytic
responses as a discriminatory factor between viral clearance and
the development of chronic infection in HCV vaccinated subjects
and underscores that this parameter is to be considered as an
important immunological readout in future vaccine trials. Indeed,
studying peptide binding and CD8 cytolytic responses could
Figure 4. Dose-inhibition curves for selected NS3-peptides to Patr-A*03:01. Binding affinity of selected NS3-peptides to Patr-A*03:01,
established by peptide binding competition assay. Patr-A*0301 cells were incubated with increasing concentrations of NS3 p59 (top left),
LGFGAYMSK (LGF, top right), AATLGFGAY (AAT, bottom left), or KGGLRPRAG (control, bottom right) in the presence of biotin-labeled indicator
peptide. Binding of indicator peptide was quantified by incubation with europium labeled streptavidin. Indicated is reduction in percentage of
europium positive cells relative to cells incubated with indicator-peptide only. The indicated IC50 values (mM) are derived from the regression curves
of three independent experiments in the case of p59, LGF and AAT, and of two individual experiments in the case of KGG. The IC50 values were
estimated using non-linear least-squares regression with the ‘‘R’’ platform for statistical computing.
doi:10.1371/journal.pone.0095103.g004
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complement the other contributing immune mechanisms previ-
ously described [11,24,25].
It should be noted that the reported data were obtained from
peripheral blood and not from the site of HCV-induced
inflammation, the liver. For ethical reasons and animal welfare,
the number of liver biopsies taken during the study, was limited
and not sufficient for the comprehensive analysis as presented in
this manuscript. Nevertheless, a direct comparison of CD8 T-cell
function between liver and peripheral blood in chimpanzees
during HCV infection, showed in essence that the cells in the
circulation reflect the situation in the liver [26,27].
The data presented here, are in line with the finding that self-
limiting HCV infection in humans is associated with the presence
of HLA-B*57 and HLA-B*27 restricted CD8 T-cell responses
[28,29]. Chimpanzee Patr-A*03:01 and Patr-B*01:01 have almost
identical B-pocket residues as compared to HLA-B*57. Moreover,
peptide binding studies have shown that both Patr-molecules may
potentially bind HLA-B*57 or HLA-B*27 [15].
In conclusion, we observed that in contrast to peptide-specific
cytokine production, the induction of an effective CD8 T-cell
effector function elicited in the context of peptide presentation by
appropriate class-I molecules appeared to be associated with
clearance of infection.
Supporting Information
Figure S1 Gating strategy for the evaluation of cytokine
production by CD4 and CD8 cells. Cells from Vac1, 2 weeks
after the last vaccine boost were stimulated with NS3vaccine and
restimulated with either NS31258–1272 (p59) or medium alone. Cells
within the lymphogate were selected, followed by selection of the
CD3 positive, CD20/CD14 negative population, subsequently
CD4 and CD8 positive cells were selected. Expression of IFNc as a
function of IL-2 or TNFa was plotted.
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Table S1 Peptide numbering of Vaccine- and Challenge-
sequence relative to HCV reference strain H77.
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